Mini-Oral Session

[MO34] Mini-Oral Session 34　Translational Research / Clinical Pharmacology 5（Basic science, Biomarker）
【E】

Sat. Feb 19, 2022 2:00 PM - 2:40 PM Room 5 (Room B-1, 2F, Kyoto International Conference Center)

Chair：Toshio Shimizu（Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital），Yoshihiko Segawa（Department of Medical Oncology, International Medical Center, Saitama Medical University）

+Add all to schedule

[MO34-1] Molecular docking analysis of Acetogenins as potential BH3 mimetic compounds targeting BCL-XL antiapoptotic protein

^○Kaynat Qurban Khimani¹, Mohd Faiz Abd Ghani², Noraziah Nordin¹ (1.Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia, 2.School of Pharmacy, KPJ Healthcare University College)

[MO34-2] MiR-125b-5p regulate epithelial-mesenchymal transition and sorafenib resistance in Hepatocellular Carcinoma

^○Akihiro Hirao¹, Yasushi Sato¹, Hironori Tanaka¹, Takahiro Tanaka¹, Tetsu Tomonari¹, Tatsuya Taniguchi¹, Koichi Okamoto¹, Naoki Muguruma¹, Kensei Nishida², Tetsuji Takayama¹ (1.Department of Gastroenterology and Oncology, Tokushima University, 2.Department of Pathophysiology, Tokushima University Graduate School of Biomedical Sciences)

[MO34-3] MORAb-202, a novel ADC, can overcome chemo-resistance derived from the FOLRα-PHB2-MDM2 axis

^○Hisato Kawakami¹, Hitomi Sakai², Takeshi Teramura³, Yuta Onodera³, Elizabeth Somers⁴, Keiji Furuuchi⁵, Toshimitsu Uenaka⁵, Ryoji Kato¹, Kazuhiko Nakagawa¹ (1.Department of Medical Oncology, Kindai University Faculty of Medicine, 2.Advanced Cancer Translational Research Institute, Showa University, 3.Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, 4.AD Franchise Special Mission, 5.Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai Inc.)

[MO34-4] Comparative study on the efficacy and exposure of molecular target agents in NSCLC PDX models with driver mutations

^○Hitomi Jo^1,2, Shigehiro Yagishita², Yoshiharu Hayashi^2,3,4, Shoraku Ryu², Mikiko Suzuki^2,3, Shinji Kohsaka⁵, Toshihide Ueno⁵, Yuji Matsumoto⁵, Hidehito Horinouchi⁷, Yuichiro Ohe⁷, Shun-Ichi Watanabe⁸, Noriko Motoi⁹, Yasushi Yatabe⁹, Hiroyuki Mano⁹, Akinobu Hamada^2,3, Kazuhisa Takahashi¹ (1.Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2.Division of Molecular Pharmacology, National Cancer Center Research Institute, 3.Department of Medical Oncology and Translational Research, Graduate School of Medical Sciences, Kumamoto University,, 4.Bioanalysis Research Department, CMIC Pharma Science Co., 5.Division of Cellular Signaling, National Cancer Center Research Institute, 6.Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, 7.Department Thoracic Oncology, National Cancer Center Hospital, 8.Department Thoracic Surgery, National Cancer Center Hospital, 9.Department of Diagnostic Pathology, National Cancer Center Hospital)

[MO34-5] Clinical significance of circulating miR-145 expression in Indian breast cancer patients

^○Prasant Yadav^1,2, Masroor Mirza^2,5, Kajal Nandi², Sudhir Kumar Jain³, Nita Khurana⁴, Alpana Saxena² (1.Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India, 2.Department of Biochemistry, Maulana Azad Medical College & Associated Hospitals, New Delhi, India, 3.Department of Surgery, Maulana Azad Medical College & Associated Hospitals, New Delhi, India, 4.Department of Pathology, Maulana Azad Medical College & Associated Hospitals, New Delhi, India, 5.Faculty of Medicine, Ala-Too International University, Bishkek, Kyrgyzstan)